CA3161119A1 - Orally disintegrating tablet - Google Patents

Orally disintegrating tablet

Info

Publication number
CA3161119A1
CA3161119A1 CA3161119A CA3161119A CA3161119A1 CA 3161119 A1 CA3161119 A1 CA 3161119A1 CA 3161119 A CA3161119 A CA 3161119A CA 3161119 A CA3161119 A CA 3161119A CA 3161119 A1 CA3161119 A1 CA 3161119A1
Authority
CA
Canada
Prior art keywords
orally disintegrating
disorder
lubricant
disintegrating tablet
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3161119A
Other languages
English (en)
French (fr)
Inventor
Taku KEMMOCHI
Hiroyuki Yamazaki
Yoshikazu Oka
Mika KOSEKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CA3161119A1 publication Critical patent/CA3161119A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3161119A 2019-11-11 2020-11-11 Orally disintegrating tablet Pending CA3161119A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPPCT/JP2019/044118 2019-11-11
PCT/JP2019/044118 WO2021095092A1 (ja) 2019-11-11 2019-11-11 口腔内崩壊錠
PCT/JP2020/042114 WO2021095779A1 (ja) 2019-11-11 2020-11-11 口腔内崩壊錠

Publications (1)

Publication Number Publication Date
CA3161119A1 true CA3161119A1 (en) 2021-05-20

Family

ID=75911893

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3161119A Pending CA3161119A1 (en) 2019-11-11 2020-11-11 Orally disintegrating tablet

Country Status (9)

Country Link
US (1) US20220387423A1 (https=)
EP (1) EP4059502A4 (https=)
JP (3) JP7395607B2 (https=)
CN (1) CN114650821A (https=)
AU (1) AU2020384456B2 (https=)
CA (1) CA3161119A1 (https=)
PH (1) PH12022551117A1 (https=)
TW (1) TWI873221B (https=)
WO (2) WO2021095092A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021095092A1 (ja) * 2019-11-11 2021-05-20 大塚製薬株式会社 口腔内崩壊錠
EP4574134A1 (en) * 2023-12-22 2025-06-25 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet comprising brexpiprazole

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010001106A1 (en) * 1996-04-16 2001-05-10 Tomohiro Yoshinari D-mannitol and its preparation
JP4358117B2 (ja) * 2001-03-06 2009-11-04 協和発酵キリン株式会社 口腔内速崩壊錠
US8153161B2 (en) * 2003-12-09 2012-04-10 Dainippon Sumitomo Pharma Co., Ltd. Medicament-containing particle and a solid preparation containing the particle
JP3996626B2 (ja) * 2004-06-22 2007-10-24 塩野義製薬株式会社 口腔内速崩壊錠
JP5004236B2 (ja) * 2005-02-09 2012-08-22 キッセイ薬品工業株式会社 口腔内崩壊錠
BRPI0808889A2 (pt) * 2007-03-13 2014-11-11 Dainippon Sumitomo Pharma Co Comprimido desintegrante oral
US8431618B2 (en) * 2008-03-31 2013-04-30 Asahi Kasei Chemicals Corporation Processed starch powder with excellent disintegration properties and manufacturing method thereof
CN102119034B (zh) * 2008-06-13 2013-05-22 大日本住友制药株式会社 在口腔中快速崩解的片剂和制备其的方法
WO2010021300A1 (ja) * 2008-08-18 2010-02-25 三菱商事フードテック株式会社 新規マンニトール打錠用賦形剤
JP5337430B2 (ja) * 2008-08-26 2013-11-06 高田製薬株式会社 口腔内速崩壊錠
JP5466880B2 (ja) * 2009-05-20 2014-04-09 京都薬品工業株式会社 口腔内崩壊錠
JP5733930B2 (ja) * 2009-09-09 2015-06-10 武田薬品工業株式会社 固形製剤
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
US9827200B2 (en) * 2012-04-24 2017-11-28 Daiichi Sankyo Company, Limited Orally disintegrating tablet and production process therefor
JP5897196B1 (ja) * 2015-10-05 2016-03-30 大同化成工業株式会社 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法
CN105412036A (zh) * 2015-12-24 2016-03-23 北京康立生医药技术开发有限公司 依匹哌唑口腔崩解片
CN106994119A (zh) * 2016-01-22 2017-08-01 浙江华海药业股份有限公司 含有依匹哌唑或其盐的口腔崩解片及其制备方法
JP6201017B2 (ja) * 2016-08-04 2017-09-20 佐藤製薬株式会社 硬度及び崩壊性に優れた口腔内崩壊錠の製造方法及び該製造方法により製造される口腔内崩壊錠
WO2021095092A1 (ja) 2019-11-11 2021-05-20 大塚製薬株式会社 口腔内崩壊錠

Also Published As

Publication number Publication date
WO2021095779A1 (ja) 2021-05-20
CN114650821A (zh) 2022-06-21
TWI873221B (zh) 2025-02-21
TW202128167A (zh) 2021-08-01
EP4059502A4 (en) 2023-12-13
PH12022551117A1 (en) 2023-08-23
JP7395607B2 (ja) 2023-12-11
JP2024026205A (ja) 2024-02-28
WO2021095092A1 (ja) 2021-05-20
AU2020384456B2 (en) 2026-03-12
AU2020384456A1 (en) 2022-06-09
JP7676510B2 (ja) 2025-05-14
EP4059502A1 (en) 2022-09-21
JP2025118718A (ja) 2025-08-13
US20220387423A1 (en) 2022-12-08
JPWO2021095779A1 (https=) 2021-05-20

Similar Documents

Publication Publication Date Title
TWI634908B (zh) 包含有７－［４－（４－苯并［ｂ］噻吩－４－基－哌－１－基）丁氧基］－１Ｈ－喹啉－２－酮或其鹽之錠劑
JP2025118718A (ja) 口腔内崩壊錠
US20100285164A1 (en) Orally Disintegrating Excipient
JP5342028B2 (ja) 口腔内崩壊錠
HUE035542T2 (hu) Brexpiprazolt vagy annak sóját és egy második hatóanyagot tartalmazó kombinációk központi idegrendszeri rendellenességek kezelésében történõ alkalmazásra
EP2308511A1 (en) Tablet quickly disintegrating in the oral cavity and method for producing the same
JP6482552B2 (ja) 界面活性剤および多価アルコールを有さず直ちに湿潤可能な経口フィルム剤形
EP3501506A1 (en) Pharmaceutical tablet composition comprising brexpiprazole
TW201507734A (zh) 口腔貼附劑
TW201840320A (zh) 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物
JP4759102B2 (ja) 経口投与用医薬組成物
JP7486258B2 (ja) 口腔内崩壊錠用顆粒、その製造方法および口腔内崩壊錠
HK40071352A (en) Orally disintegrating tablet
HK40066890A (zh) 口腔崩解片剂
EA051121B1 (ru) Перорально распадающаяся таблетка
CN103282051A (zh) 口腔内崩解片剂
JP6457582B2 (ja) ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤
TW201113051A (en) Oral disintegrating tablet and manufacturing method thereof
TW201607556A (zh) 以二階段濕式造粒步驟製造之崩解性粒子組成物及含有該組成物之口腔內崩解錠劑
TW201021832A (en) Pharmaceutical composition for oral administration
JP6668666B2 (ja) イルベサルタンを含有する医薬組成物及びその製造方法
TWI306763B (https=)
TW201422224A (zh) 含有達泊西汀游離鹼的口腔用組成物
CN110582272A (zh) 含有贝西福韦酯或其药剂学上容许的盐的颗粒、包含此颗粒的药剂学组成物及其制备方法
JP2007169263A (ja) 固形製剤および製剤組成物

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241101

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241101

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241115

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241223

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250407

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251031

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260130

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260203